Barclays Issues Positive Forecast for Xeris Biopharma (NASDAQ:XERS) Stock Price

Xeris Biopharma (NASDAQ:XERS) had its price objective hoisted by Barclays from $14.00 to $18.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other equities research analysts also recently commented on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. HC Wainwright increased their price target on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday, November 6th. Leerink Partners raised their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Finally, Piper Sandler reiterated a “neutral” rating and set a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research report on Friday, November 6th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $16.52 on Wednesday. Xeris Biopharma has a one year low of $5.25 and a one year high of $16.57. The stock has a 50-day moving average of $10.08 and a 200 day moving average of $7.75. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -330.33 and a beta of 0.61. The company has a debt-to-equity ratio of 3.89, a quick ratio of 1.02 and a current ratio of 2.15.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 147.75%. The business had revenue of $107.23 million for the quarter, compared to analysts’ expectations of $101.68 million. On average, sell-side analysts forecast that Xeris Biopharma will post 0.15 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total value of $312,250.00. Following the transaction, the insider directly owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the transaction, the insider owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 168,332 shares of company stock valued at $1,678,971. Insiders own 4.35% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors have recently bought and sold shares of the stock. Chicago Partners Investment Group LLC increased its position in Xeris Biopharma by 16.3% in the third quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock worth $136,000 after buying an additional 1,861 shares in the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock valued at $464,000 after acquiring an additional 1,940 shares during the period. Allworth Financial LP grew its stake in shares of Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock valued at $34,000 after acquiring an additional 2,000 shares during the period. Jacksonville Wealth Management LLC increased its holdings in Xeris Biopharma by 11.8% in the 3rd quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock worth $182,000 after acquiring an additional 2,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Xeris Biopharma by 7.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock worth $332,000 after acquiring an additional 2,190 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Recent Xeris Biopharma Headlines

Investors following XERS have been watching these headlines:

• Positive Sentiment: Barclays raised its price target to $18 from $14 and maintained an “Overweight” rating, citing a more bullish outlook. TickerReport article
• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $18 target while lifting its earnings estimates: FY2026 EPS to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The higher projections reinforce expectations for improving profitability. MarketBeat Xeris coverage
• Positive Sentiment: Wall Street brokerage coverage was characterized as “Moderate Buy,” and Wall Street Zen upgraded the stock, adding to the broadly favorable analyst tone. Brokerage ratings article Wall Street Zen upgrade article

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.